Background: The blockade of PD-1-PD-L1 pathway is emerging as an effective therapeutic strategy for several advanced cancers. But the immune regulatory role of PD-1-PD-L1 pathway is not clear in colorectal cancer (CRC) patients. This study aims to evaluate the role of PD-1-PD-L1 pathway in CD8 þ T-cell functions in tumour-draining lymph nodes (TDLNs) and tumours of CRC patients.
The programmed death 1 (PD-1, also known as CD279) is a co-inhibitory receptor that is inducibly expressed on T cells upon activation (Chen, 2004; Keir et al, 2008) . PD-1 is rapidly upregulated on antigen-specific T cells responding to viral infection, but quickly downregulated upon removal of the antigen in acute viral infection (Barber et al, 2006) . By contrast, during chronic infections such as LCMV in mice (Barber et al, 2006) and HIV (Day et al, 2006; Trautmann et al, 2006) or HCV in patients (Urbani et al, 2006; Golden-Mason et al, 2007; Nakamoto et al, 2008) , virus-specific CD8 T cells show sustained expression of PD-1 that triggers T-cell dysfunction or exhaustion by interaction with its ligand PD-L1 (B7-H1). Blocking of PD-1-PD-L1 interactions can restore T-cell function to reverse the course of chronic infection.
The PD-1-PD-L1 pathway has also been implicated in T cell exhaustion in cancer. PD-1 is highly expressed on tumourinfiltrating CD8 þ T cells in multiple solid tumours (Thompson et al, 2007; Ahmadzadeh et al, 2009; Lyford-Pike et al, 2013) , particularly on tumour-specific CD8 þ T cells. PD-1 þ CD8 þ T cells exhibit an exhausted phenotype as defined by impairment of proliferation, cytokine production and cytotoxicity. Meanwhile, PD-L1 is expressed in several different cancers, which is strongly associated with poor prognosis (Thompson et al, 2004; Ohigashi et al, 2005; Hamanishi et al, 2007; Keir et al, 2008) . The interference with PD-1-PD-L pathway using blocking monoclonal antibodies (mAbs) against PD-1 or PD-L1 is emerging as an effective method for reversing cancer immunosuppression and thereby causing tumour regression in patients with advanced disease. Such treatments have shown promising clinical results not only for tumours classically considered to be immunogenic such as melanoma and renal cell carcinoma, but also for common epithelial malignancies such as non-small cell lung cancer, which has been considered to be non-immunogenic and poorly responsive to immune-based therapies Topalian et al, 2012) . But, in the same clinical trials, no objective responses were observed in patients with colorectal cancer (CRC). The reason for the different therapeutic effects of targeting PD-1-PD-L pathway between CRCs and other cancers is not known. It was reported that the presence of tumour-infiltrating lymphocytes (TILs) in primary CRC presages an improved clinical outcome (Ropponen et al, 1997; Naito et al, 1998) . A high density of infiltrating memory and effector memory T cells (T EM ) within CRCs was associated with decreased invasiveness, lower stage and improved survival. The type and density of T cells in CRCs were found to have stronger prognostic significance than conventional tumour-node-metastasis (TNM) staging (Pages et al, 2005; Galon et al, 2006) . These studies provide clear evidence that anti-tumour T cell responses play an important role in determining the clinical outcome from CRC. However, the expression and regulatory effects of PD-1 on CD8 þ TILs from CRC have not been reported, and the roles of PD-1-PD-L1 pathway in regulating T cell responses against CRC are not well studied. It was reported that PD-1 is expressed on T cells of peripheral blood and PD-L1 was detectable in epithelial cells of normal colonic mucosa and cancer cells in CRC patients (Arai et al, 2012; Droeser et al, 2013) . But, PD-L1 expression is paradoxically associated with improved survival of CRC patients (Droeser et al, 2013) .
The tumour-draining lymph node (TDLN) is the site in which tumour-specific CD8 þ T cells are typically activated by antigenpresenting cells, and antitumor immune responses are initiated. Meanwhile, it is also the preferential site of initial tumour metastases. The local microenvironment in the TDLNs becomes a key determinant in setting the course of the subsequent immune response to the tumour (Kim et al, 2006) . It was reported that a high density of CD45RO þ T cells in lymph node metastasis of CRC was associated with improved prognosis (Oberg et al, 2002) . PD-1 is inducibly expressed on T cells upon activation, but the effect of PD-1 signalling in activated CD8 þ T cells in TDLNs has not been reported.
In this study, we show that PD-1 is highly expressed on CD8 þ T cells in tumour-free lymph nodes (TFLNs) and tumours. The functions of PD-1 þ CD8 þ T cells are intact in TFLNs, but impaired in tumours. PD-L1 is expressed in tumours and tumourinvaded lymph nodes (TILNs) rather than TFLNs. Moreover, expression of PD-L1 is closely associated with the function of PD-1 þ CD8 þ T cells in tumours. Our findings suggest that PD-1 signalling has no negative regulation on CD8 þ T cells in TDLNs, but do severely inhibit functions of CD8 þ T cells in tumours. Intracellular cytokine induction. Cells from tumour suspensions and draining lymph nodes were stimulated with phorbolmyristate acetate (PMA; 2 ng ml À 1 ) and ionomycin (1 mg ml À 1 ) in the presence of Brefeldin A (eBioscience) for 4 h at 371C. Cells were subsequently collected and stained for surface markers followed by fixation with IC fixation Buffer (eBioscience) for 20 to 30 min at room temperature. Then, the cells were washed twice with 1 Â Permeabilization Buffer (eBioscience) and stained with IL-2, IFN-g antibody. After washing, cells were fixed with 1% PFA and stored at 41C until acquisition.
MATERIALS AND METHODS
Immunohistochemistry. Both tumour tissues and lymph nodes were fixed with formalin, and embedded in paraffin wax. Tissue sections were cut into 5-mm-thick consecutive sections and dried at 701C for 30 min. Dried sections were deparraffinised in xylene and rehydrated through graded ethanol solutions to water. Antigens were retrieved by heating the tissue sections in citrate buffer (pH 6.0) by microwaves. To block endogenous peroxidase activity, all of the sections were treated with 100% methanol containing 0.3% H 2 O 2 for 15 min. Non-specific binding was blocked with 10% normal goat serum (Life Technologies, Inc). The sections were incubated with mouse anti-PD-L1 mAbs (clone 27A2, MBL, Nagoya, Japan) or purified mouse IgG2b, k isotype ctrl antibody (MCP-11, BioLegend, San Diego, CA, USA) overnight at 41C. The sections were then incubated with HRP-labelled goat anti-mouse secondary antibody (Santa Cruz, Dallas, TX, USA).
Diaminobenzene was used as the chromogen and haematoxylin as the nuclear counterstain.
Statistical analysis. Statistical analysis was done with GraphPad Prism 5 software (Graphpad, San Diego, CA, USA). Two-tailed t-test for paired or unpaired samples were applied to determine the significance. A correlation was tested for significance by the Spearman's rank correlation test. Data were considered statistically significant at Po0.05.
RESULTS
Patient characteristics. Forty-nine patients (male 25, female 24) with CRC undergoing radical resection were enrolled into our study. The characteristics of patients are shown in Table 1 . A total of 134 lymph nodes from 49 patients were investigated. Two patients had only one lymph node available. In total, 132 lymph nodes were individually analysed in 47 patients who had two or more lymph nodes.
PD-1 expression is upregulated on CD8
þ T cells in TDLNs and tumours of CRC patients. To explore the role of PD-1 signalling in regulating anti-tumour CD8 þ T cell responses in CRC patients, we first assessed the expression of PD-1 on CD8 þ T cells in tumour tissues, TDLNs and peripheral blood of the same patients. Single-cell suspensions of tumour digests, minced lymph node and PBLs were analysed directly by flow cytometry with anti-CD3, CD8 and PD-1 antibodies. The frequencies of PD-1 þ cells among CD8 T cells were significantly higher in TDLNs (mean: 22.5% ± 12.9%) than those in PBLs (7.4% ± 5.2%; Po0.0001), but remarkably lower than those in tumours (36.6% ± 15.7%; Po0.0001). Similar observations were made when PD-1 expression was analysed as mean fluorescence intensity (MFI; Figure 1A and B).
Tumour metastasis in draining lymph nodes was routinely examined by pathologists. The mean frequency of PD-1 þ cells and the mean MFI of PD-1 expression were significantly higher for CD8 þ T cells in TILNs than those in TFLNs (35.7% ± 18.2% vs 19.8%±12.4%, P ¼ 0.0007 and 15.9±9.4 vs 9.6±4.2, P ¼ 0.0024, respectively; Figure 1C ). There was no difference in the expression of PD-1 on CD8 þ T cells between TILNs and tumour tissues for both the percentage of PD-1 þ cells (37.8% ± 21.6% vs 34.1%±17.3%; P ¼ 0.6447) and the MFI of PD-1 expression (18.3 ± 10.7 vs 13.1 ± 5.4; P ¼ 0.1468; Figure 1D ). Similar observation was also made between the lymph nodes from the same patients (data not shown). Collectively, our results demonstrated that PD-1 expression was upregulated on CD8 þ T cells in TDLNs, although it was lower than that in tumour. Moreover, high-level expression of PD-1 was correlated with the presence of metastatic tumour cells.
PD-1
þ CD8 þ T cells are not functionally impaired in TFLNs, but dysfunctional in tumours. To compare the functions of PD-1 þ and PD-1 À CD8 þ T cells, we first assessed cytokine production of CD8 þ T cells in TDLNs and tumours from the same patients. Because tumour metastasis markedly decreased lymphocytes in lymph nodes (data not shown), which was not enough for studying their functions in vitro, the following functional studies were done with the lymphocytes of TFLNs. The freshly isolated lymphocytes were stimulated with PMA and ionomycin for 4 h, and intracellular cytokines were examined in gated CD3 þ CD8 þ T cells. As shown for one representative CRC patient in Figure 2A and for several CRC patients in Figure 2B , compared with PD-1
þ TILs not only exhibited markedly reduced percentages of IL-2-(16.1% ± 12.6% vs 33.4% ± 19.1%,
, but also expressed lower levels of IL-2 (39.3±33.9 vs 72.7 ± 44.5,
These data are consistent with the previous findings that PD-1 upregulation is associated with the impairment of cytokine production of tumour-infiltrating CD8 þ T cells upon ex vivo stimulation (Ahmadzadeh et al, 2009) . In contrast, the percentage (IL-2: 37.6% ± 8.9% vs 24.6% ± 10.6%, Po0.0001; IFN-g: 73.8% ± 13.9% vs 25.1% ± 16.7%, Po0.0001; PD-1 þ vs PD-1 À , respectively) and the amount (MFI; IL-2: 101.8 ± 27.1 vs 77.0 ± 33.4, P ¼ 0.0252; IFN-g: 735.8 ± 686.4 vs 296.7±346.2, Po0.0001; PD-1 þ vs PD-1 À , respectively) of IL-2 and IFN-g production were increased in PD-1 þ CD8 þ T cells compared with PD-1 À CD8 þ T in TFLNs. T-cell functions are associated with their differentiation/ activation status, which could be identified by staining with CD45RA and CCR7. In tumour tissues, the majority of CD8 þ T cells (88.9%±4.1%) fell into the subset of T EM (CD45RA
þ phenotype were rarely detected. However, some lymph nodes had much more naïve CD8 þ T cells (22.5% ± 16.6%) besides the majority population of T EM cells (61.2%±17.2%; Figure 3A ). Figures 2B and 3B ). There was no significant difference of IFN-g production in both percentage and MFI of IFN-g-producing cells between PD-1 þ and PD-1 Figure 3B ). However, the low frequency of CD45RA þ CD8 þ T cells had little influence on the percentage of IFN-g-producing cells in tumour-infiltrating CD8 þ T cells. PD-1 þ cells still produced less IFN-g in both percentage and MFI of IFN-g-producing cells than PD-1 À cells (percentage: 61.6% ± 11.5% vs 72.6% ± 8.1%, P ¼ 0.0093; MFI: 762±419 vs 984±441.1, P ¼ 0.0259) in the CD45RA À CD8
þ T cell population of TILs ( Figure 3B ). These results indicated that the expression of PD-1 was inversely correlated with the ability of CD8 þ T cells to produce IFN-g in tumour, but had no significant effect on the cytokine production of CD8 þ T cells in TFLNs. Next, we assessed the cytotoxicity of CD8 þ T cells in TFLNs and tumours from the same patient by detecting the expression of granzyme B and perforin. PD-1 þ CD45RA À CD8 þ T cells expressed a higher level of perforin (range: 36.6-68.3%, mean: 54.6%) than PD-1 À CD45RA À CD8 þ T cells (range: 25.6-59.7%, mean: 43.8%) in TFLNs ( Figure 4A ; P ¼ 0.0004). Although a higher level of perforin was also measured in PD-1 À (range: 1.2-4.5%, mean: 2.4%) than PD-1 þ CD45RA À CD8 þ TILs (range: 0.4-1.4%, mean: 0.8%, P ¼ 0.0272), antigen-experienced CD45RA À CD8 þ T cells expressed extremely low level of perforin in tumours ( Figure 4A ). On the contrary, tumour-infiltrating CD45RA À CD8 þ T cells expressed a higher level of granzyme B than that in TFLNs, and no significant difference in granzyme B expression was observed between PD-1 þ and PD-1 À CD8 þ TILs ( Figure 4B ). While in draining lymph nodes, PD-1 þ CD8 T cells still express a higher level of granzyme B (range: 15.2-42.3%, mean: 31.4%) than PD-1 À CD45RA À CD8 þ T cells (range: 6.8-36.6%, mean: 21.1%, Po0.0001; Figure 4B ). These results demonstrated that CD8 þ TILs in CRC had a serious defection in perforin expression, BRITISH JOURNAL OF CANCER Association of PD-1 with CD8 þ T cells in CRC although they stored the highest amount of granzyme B, and upregulation of PD-1 even more impaired perforin production, which will lead to a defect of cytotoxicity. However, PD-1 þ CD8 þ T cells were competent for expression of granzyme B and perforin in TFLNs.
PD-L1 expression is related with functional impairment of CD8 þ T cells in tumours rather than TFLNs. To evaluate the relation of PD-L1 expression to the functions of PD-1 þ
CD8
þ T cell in TFLNs and tumours, we examined PD-L1 expression by immunohistochemistry. PD-L1 was clearly expressed in tumours, not in adjacent tissues ( Figure 5A ). The expression of PD-L1 was greatly varied in tumour tissues from different patients, which was scored as 0, 1, 2 and 3 grades in 4 (22.2%), 4 (22.2%), 7 (38.9%) and 3 (16.7%) cases, respectively ( Figure 5B ). More importantly, the expression level of PD-L1 was closely correlated with the impairment of cytokine production of PD-1 þ CD8 þ T cells in tumour (R ¼ À 0.87, Po0.0001; Figure 5C ).
TFLNs had no or very low-level expression of PD-L1. Moreover, PD-L1 expression in TFLNs was observed in the germinal follicles, not in T-cell-dependent paracortical areas ( Figure 5D ), suggesting that PD-1 þ CD8 þ T cells has no PD-L1 binding in TFLNs. But, PD-L1 was moderately expressed in tumour nests of TILNs, which was consistent with the higher expression of PD-1 on CD8 þ T cells in TILNs ( Figure 5E ). These results suggested that the functions of PD-1 þ CD8 þ T cells should be impaired in TILNs.
DISCUSSION
In the present study, we have systemically examined the expression of the inhibitory receptor PD-1 on CD8 þ T cells in tumour, TDLNs and peripheral blood, and found that PD-1 is markedly expressed on CD8 þ T cells in both tumour and TFLNs compared with that in peripheral blood, although the expression of PD-1 on PD-1 has been found to be expressed on a large proportion of TILs from many different tumour types (Thompson et al, 2007; Ahmadzadeh et al, 2009; Lyford-Pike et al, 2013) . Increased PD-1 expression on CD8 þ TILs may either reflect an anergic or exhausted state, as has been suggested by decreased cytokine production by PD-1 þ compared with PD-1 À TILs (Ahmadzadeh et al, 2009 ). However, the expression pattern of PD-1 and its relation with T-cell functions in TDLNs have rarely been studied. Here, we examined PD-1 expression on CD8 þ T cells in TDLNs and contrasted its functional profile with CD8 þ T cells in tumours. We found that even in TFLNs, PD-1 expression is markedly upregulated on CD8 þ T cells compared with that in peripheral blood, although CD8 þ T cells of TFLNs express lower level of PD-1 than CD8
þ TILs. However, in contrast with the
þ T cells in TFLNs are functionally intact. They even express higher granzyme B and perforin than antigen-experienced PD-1 À CD8 þ T cells of TFLNs, suggesting a stronger anti-tumour cytotoxicity. PD-1 has been considered as a primary marker for exhausted T cells. However, PD-1 expression on T cells is not always associated with exhausted phenotype (Fourcade et al, 2009) . Our data show that PD-1 þ CD8 þ T cells are bona fide effector T cells in TFLNs, while their functions are impaired in tumours. The remarkable disparity of PD-1 þ CD8 þ T-cell function between TFLNs and tumours cannot be explained by the expression level of PD-1 on CD8 þ T cells, because PD-1 þ CD8 þ T cells express more granzyme B and perforin than antigen-experienced PD-1 À CD8 þ T cells in TFLNs. But they are closely related with the expression of PD-L1 in TFLNs and tumours. Moreover, the level of PD-L1 in tumours is negatively correlated with IFN-g production of PD-
TILs. These results demonstrate that PD-1 upregulation, which is induced by T-cell priming or reactivation in TDLNs, alone has no direct effect on the functionality of activated CD8 þ T cells. Without ligand binding in the TDLN, PD-1 may just be an P values were calculated based on the paired t-test between PD-1 þ and PD-1 À subsets in TFLNs or tumours.
BRITISH JOURNAL OF CANCER Association of PD-1 with CD8 þ T cells in CRC activation marker of T cells. Once activated PD-1 þ CD8 þ T cells migrate into tumour, the binding of PD-1 with PD-L1 inhibit cytokine production and the cytolytic activity of CD8 þ T cells, leading to exhaustion or dysfunction of T cells.
Human CRCs with a high density of infiltrating memory and effector memory (CD45RO þ ) T cells were less likely to disseminate to lymphovascular and perineural structures and to regional lymph nodes (Pages et al, 2005) . The frequency of CD45RO þ T cells in TILNs of CRC was also associated with improved prognosis (Oberg et al, 2002) . We previously showed that CD45RO þ CD8 þ T cells were major IFN-g-producing cells compared with CD45RO
À CD8 þ T cells in TDLNs (Deng et al, 2010) . In the present study, we further identify the differentiation/ activation statue of CD8 þ T cells in tumour and TDLNs of CRC by flow cytometry and to show that the majority of antigenexperienced CD8 þ T cells in both locations are effector memory phenotype (CD45RA À CCR7 À ) and highly express PD-1. However, their functions are completely opposite. These results suggest that TFLNs may be a major provider for competent antitumour CD8 þ T cells. Although they are severely inhibited by various suppressive signalling, such as PD-1-PD-L1 pathway, once infiltrating into tumours, they still play important roles in tumour progression.
PD-L1 is expressed at high levels in several different cancers, and high expression of PD-L1 on tumours is usually strongly associated with poor prognosis. But the clinical significance of PD-L1 expression in CRC is still not clear. Droeser et al (2013) recently analysed the expression of PD-L1 in CRC by using a tissue microarray and found that PD-L1 expression is paradoxically associated with improved survival in DNA mismatch repairproficient rather than -deficient CRC. They also found that strong PD-L1 expression in CRC appeared to be correlated with high numbers of CD8 þ TILs, which did not express the PD-1 and did not measure the functions of CD8 þ TILs. The mechanism underlying the favourable effect of PD-L1 overexpression in CRC was not clear. Our study showed that PD-L1 expression in CRC was inversely associated with the ability of PD-1 þ CD8 þ TILs to produce IFN-g, and PD-1 was markedly upregulated on CD8 þ TILs, which was also associated with the impairment of cytokine and perforin production of CD8 þ TILs. However, it should be noted that the functional difference between PD-1 þ and PD-1
þ TILs is not very big, and the expression of perforin in PD-1 À CD8 þ TILs is already extremely low in CRC. In addition, no objective responses have been observed in CRC patients in the phase I clinical trial with anti-PD-1 or PD-L1 antibody Topalian et al, 2012) . These results suggest that other molecules and inhibitory pathways are likely involved in T-cell exhaustion of CRC. It has been recently reported that the inhibitory receptors LAG-3, Tim-3 and BTLA were co-expressed with PD-1 on CD8
þ TILs or tumour-specific CD8 þ T cells, which impair the functions of tumour-specific T cells (Matsuzaki et al, 2010; Sakuishi et al, 2010; Fourcade et al, 2012) . Thus, it will be intriguing to identify the dominant inhibitory receptor for T-cell dysfunction in CRC. In summary, we report that PD-1 expression is upregulated on CD8 þ T cells in both TDLNs and tumours. PD-1 þ CD8 þ T cells are competent for production of cytokines and perforin in TFLNs in which PD-L1 is not expressed, but exhibits less effector functions than PD-1 À CD8 þ T cells in tumours in which PD-L1 is highly expressed. These results support a role of PD-1 pathway to suppress T-cell effector functions in tumours, not in TFLNs. 
